AKTS · Aktis Oncology, Inc.

Aktis Oncology announced its first quarter 2026 financial results and business highlights via press release on May 11, 2026. The company reported collaboration revenue of $3.2 million, up from $1.4 million in the prior year period, driven by progress in its research collaboration with Eli Lilly and Company using the cost-incurred input method for revenue recognition. Research and development expenses rose to $20.0 million from $15.9 million, primarily due to Phase 1b clinical trial costs for AKY-1189, IND-enabling studies for AKY-2519, and increased hiring with stock-based compensation. General and administrative expenses increased to $5.9 million from $3.7 million, reflecting higher employee costs and public company expenses. This resulted in a net loss of $18.3 million, compared to $15.0 million last year, partially offset by $4.4 million in interest income.

Balance sheet strengthened significantly with cash, cash equivalents, and marketable securities at $538.5 million as of March 31, 2026, up $311.7 million from year-end 2025, mainly from net proceeds of a January 2026 IPO raising approximately $365.4 million gross at $18.00 per share. This cash position supports operations into 2029.

CEO Matthew Roden emphasized momentum in the miniprotein radioconjugate platform, highlighting initiation of the AKY-2519 Phase 1b trial in mCRPC (PLUVICTO-naïve and experienced patients) and plans for a second basket trial in lung, colorectal, and other B7-H3 tumors in H2 2026. AKY-1189 enrollment continues in Nectin-4 expressing tumors including urothelial, breast, lung, colorectal, cervical, and head/neck cancers, with FDA Fast Track for mUC. Preliminary data for both programs expected in 2027. ASCO presentation of AKY-2519 imaging/dosimetry data is upcoming May 29-June 2, 2026. Corporate milestones include in-house GMP facility operational in H2 2026 and two early pipeline programs toward IND-enabling in Q1 2027. Appointment of Glenn Gormley to the Board enhances scientific oversight.